New York, NY November 1, 2017 – Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announced today that an updated buyback program has been unanimously approved by Daxor’s Board of Directors.
The Board of Directors of Daxor has voted to re-authorize the company’s share buyback for an amount of up to 300,000 shares for the next 12 months. The Company formerly had in place a program that authorized up to 250,000 to be repurchased annually. Stated CEO, Michael Feldschuh, “In light of the value that the shares represent at current market prices and management’s philosophy of increasing shareholder value, I welcome this policy by the Board of Directors of the Corporation.”
Daxor Corporation manufactures and markets the BVA-100 Blood Volume Analyzer, which is used in conjunction with Volumex, Daxor’s single-use diagnostic kit. For more information regarding BVA and the Daxor BVA-100, visit Daxor’s website at www.Daxor.com.